- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | 192 | PR Newswire | STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the... ► Artikel lesen | |
| 04.11. | Swedish Orphan Biovitrum AB: David Meek is proposed as new Chair of the Board of Directors of Sobi | 212 | PR Newswire | The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary... ► Artikel lesen | |
| 03.11. | Swedish Orphan Biovitrum Aktie: Vision mit Erfolg gekrönt | gurupress.de | |||
| 30.10. | Swedish Orphan Biovitrum AB: New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference | 299 | PR Newswire | STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM AB ADR Aktie jetzt für 0€ handeln | |||||
| 27.10. | Swedish Orphan Biovitrum AB: Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN | 465 | PR Newswire | Statistically significant 68% (pAll secondary endpoints favoured treatment with pegcetacoplan, including:
- Stabilised eGFR, a key measure of kidney function- 71% of patients achieved... ► Artikel lesen | |
| 25.10. | Swedish Orphan Biovitrum AB: Invitation: Sobi's Aspaveli and the Phase 3 VALIANT data in Nephrology call | 230 | PR Newswire | STOCKHOLM, Oct. 25, 2024 /PRNewswire/ --
VALIANT Phase 3 results after presentation at ASN
Investors, analysts, and members of the media are invited to a conference call on Tuesday... ► Artikel lesen | |
| 25.10. | SWEDISH ORPHAN BIOVITRUM AB: Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call | 2 | Cision News | ||
| 25.10. | Sobi meldet robustes Wachstum im dritten Quartal und hebt Prognose für 2024 an | 5 | Investing.com Deutsch | ||
| 25.10. | Earnings call: Sobi reports robust Q3 growth, upgrades 2024 guidance | 5 | Investing.com | ||
| 24.10. | Swedish Orphan Biovitrum Q3 Results Climb, Lifts FY24 Revenue View; Stock Rises | 1 | RTTNews | ||
| 24.10. | Swedish Orphan Biovitrum AB: Sobi Q3 2024 report: Strong growth and significant pipeline momentum | 307 | PR Newswire | STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024
Third Quarter 2024
Total revenue increased... ► Artikel lesen | |
| 09.10. | Swedish Orphan Biovitrum AB: Invitation: Sobi's Q3 2024 report | 192 | PR Newswire | STOCKHOLM, Oct. 9, 2024 /PRNewswire/ --
Sobi plans to publish its report for the third quarter of 2024 on 24 October 2024 at 08:00 CEST.
Investors, analysts, and the media are invited... ► Artikel lesen | |
| 30.09. | Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi | 225 | PR Newswire | STOCKHOLM, Sept. 30, 2024 /PRNewswire/ -- As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are... ► Artikel lesen | |
| 13.09. | Sobi and Enable Injections partner for Aspaveli distribution | 3 | Pharmaceutical Technology | ||
| 12.09. | Sobi, Enable Partner on Subcutaneous Drug Delivery | 2 | Contract Pharma | ||
| 12.09. | Enable Injections, Sobi Partner To Distribute EnFuse Injector For Subcutaneous Delivery Of Aspaveli | 1 | RTTNews | ||
| 12.09. | Swedish Orphan Biovitrum AB: Sobi and Enable Injections announce agreement to develop and distribute Aspaveli in combination with enFuse in Sobi territories | 243 | PR Newswire | STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) and Enable Injections, Inc. (Enable) today announced an international development and distribution agreement across Sobi territories... ► Artikel lesen | |
| 12.09. | SWEDISH ORPHAN BIOVITRUM AB: Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories | 2 | Cision News | ||
| 29.08. | Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares | 380 | PR Newswire | STOCKHOLM, Aug. 29, 2024 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible... ► Artikel lesen | |
| 14.08. | Sobi and Apellis' pegcetacoplan shows promise in phase 3 rare kidney disease study | 8 | PMLiVE |
Seite:
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -15,59 % | ASML, Defama, Evotec, Mercedes-Benz, Smartbroker, Süss MicroTec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +0,28 % | Übernahmefantasie und Momentum: BioNTech, Rheinmetall, Vidac Pharma Aktie | BioNTech will seine Pipeline für den Kampf gegen Krebs stärken und die chinesische Biotechfirma Biotheus übernehmen. Dafür legen die Mainzer für das auf die Entwicklung von Therapien für Krebs- und... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +0,18 % | Opening Bell: Bitcoin, Tesla, Moderna, Netflix, Palantir, Nvidia | Vor dem Wochenende ging es für den Dow Jones um 0,7 Prozent abwärts. Auch auf Wochensicht fuhr er Verluste ein, hier gab er 1,3 Prozent ab. Der Nasdaq 100 verlor sogar 2,4 Prozent in der vergangenen... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
| RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |
Das Unternehmen SWEDISH ORPHAN BIOVITRUM AB ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SWEDISH ORPHAN BIOVITRUM AB ADR finden Sie auf Wallstreet Online.
